http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101181627-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 |
| filingDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101181627-B1 |
| titleOfInvention | Pharmaceutical composition for the treatment of prostate cancer comprising A3 adenosine receptor agonist |
| abstract | The present invention provides a selective A 3 adenosine receptor agonist, 2-chloro-N 6- (3-iodobenzyl) -4′-thioadenosine-5′-N-methyluronamamide (thio-Cl- IB-MECA), N 6- (3-iodobenzyl) -4′-thioadenosine-5′-N-methyluronamamide (thio-IB-MECA), or pharmaceutically acceptable salts thereof It relates to a pharmaceutical composition for preventing or treating prostate cancer. The A 3 adenosine receptor agonists, thio-Cl-IB-MECA or thio-IB-MECA according to the present invention not only have low toxicity, but also are more selective than androgen receptor dependent or non-comparable to other A 3 adenosine receptor agonists. It inhibits the growth of dependent prostate cancer cells and thus is useful for the prevention or treatment of prostate cancer.n n n n Adenosine receptors, adenosine receptor agonists, thio-Cl-IB-MECA, thio-IB-MECA, cancer, prostate cancer, anticancer agents |
| priorityDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.